Comparison of Two Telemonitoring Auto-titrating Modalities in OSA Patients

Sponsor
Basque Health Service (Other)
Overall Status
Completed
CT.gov ID
NCT03734341
Collaborator
(none)
50
1
2
9.2
5.4

Study Details

Study Description

Brief Summary

This study compares the titration pressures achieved through two auto-titrating modalities, a new incremental fixed pressure mode versus routine auto-adjusting pressure mode, in CPAP-naïve obstructive sleep apnea patients.

The aim of the study is to verify that this new modality achieves a lower titration pressure.

Detailed Description

In patients with obstructive sleep apnea (OSA) on CPAP treatment, a CPAP titration test is usually performed to achieve the optimal pressure to maintain upper airway patency, abolish obstructive respiratory events and reduce the occurrence of adverse events. This pressure is called titration pressure.

Until now, we used to perform, after an adaptation period, a single-night outpatient test with an automated device preset on auto-adjusting pressure modality (APAP).

The incremental fixed pressure modality (EZ START) was initially developed to ease patients into having a positive sleep therapy experience from the very beginning. This mode gradually increases air pressure night-by-night until the preset therapeutic pressure is reached. In each good therapy session, the device performs in fixed pressure overnight and we get a real residual apnea-hypopnea index (rAHI).

For this study, we will use the same device (DreamStation auto CPAP, Philips Respironics, Murrysville, PA, USA), a web-based system to telemonitor patient therapy (EncoreAnywhere) and perform for each individual patient the two modalities in a telemonitoring crossover randomized single-blind (patient) way.

Study Design

Study Type:
Interventional
Actual Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
A Telemonitoring Crossover Study Comparing a New Incremental Fixed Pressure Titration Modality Versus Auto-adjustable Titration for CPAP-naïve Obstructive Sleep Apnea Patients
Actual Study Start Date :
Apr 1, 2018
Actual Primary Completion Date :
Sep 1, 2018
Actual Study Completion Date :
Jan 7, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: EZ START Titration

CPAP titration test performed with an auto CPAP device preset on incremental fixed pressure modality. If the titration pressure is achieved (in a 14-day maximum period) the device will be immediately and remotely preset in CPAP modality with EZ START pressure (if any) for a 14-day period to check the titration pressure performance in a short-time period. Afterwards, the device will be remotely preset on the next modality: auto-adjusting pressure (no wash-out period).

Device: EZ START Titration
The auto CPAP device gradually increases air pressure night-by-night until the preset therapeutic pressure is reached. Pressure range: from 5 to 14 cmH2O. Ramp: 4cmH2O, 20 minutes. Mask: nasal (if no contraindication). Titration pressure: fixed pressure that reduces rAHI below 10, mask leak below 10% of the session, time session above 4 hours.
Other Names:
  • DreamStation auto CPAP
  • Philips Respironics
  • EncoreAnywhere
  • Device: APAP Titration
    The auto CPAP device continuously adjusts the pressure in real time to the minimum pressure needed to maintain upper airway patency at any moment. Pressure range: 5 to 14 cm H2O. Ramp: 4cmH2O, 20 minutes. Mask: nasal (if no contraindication). Titration pressure: visual analysis pressure that reduces rAHI below 10 during 90% of the session, mask leak below 10% of the session, therapeutic session above 4 hours.
    Other Names:
  • DreamStation auto CPAP
  • Philips Respironics
  • EncoreAnywhere
  • Active Comparator: APAP Titration

    CPAP titration test performed with an auto CPAP device preset on auto-adjusting pressure modality. If the titration pressure is achieved (in a 14-day maximum period) the device will be immediately and remotely preset in CPAP modality with APAP pressure (if any) for a 14-day period to check the titration pressure performance in a short-time period. Afterwards, the device will be remotely preset on the next modality: incremental fixed pressure (no wash-out period).

    Device: EZ START Titration
    The auto CPAP device gradually increases air pressure night-by-night until the preset therapeutic pressure is reached. Pressure range: from 5 to 14 cmH2O. Ramp: 4cmH2O, 20 minutes. Mask: nasal (if no contraindication). Titration pressure: fixed pressure that reduces rAHI below 10, mask leak below 10% of the session, time session above 4 hours.
    Other Names:
  • DreamStation auto CPAP
  • Philips Respironics
  • EncoreAnywhere
  • Device: APAP Titration
    The auto CPAP device continuously adjusts the pressure in real time to the minimum pressure needed to maintain upper airway patency at any moment. Pressure range: 5 to 14 cm H2O. Ramp: 4cmH2O, 20 minutes. Mask: nasal (if no contraindication). Titration pressure: visual analysis pressure that reduces rAHI below 10 during 90% of the session, mask leak below 10% of the session, therapeutic session above 4 hours.
    Other Names:
  • DreamStation auto CPAP
  • Philips Respironics
  • EncoreAnywhere
  • Outcome Measures

    Primary Outcome Measures

    1. Titration pressure [14-day maximum period]

      Titration pressure in any modality

    Secondary Outcome Measures

    1. CPAP Adherence [14-day period]

      Adjusted adherence: days of use (%) * hours of use (mean)

    2. CPAP Efficacy [14-day period]

      Residual AHI (mean) in the period

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age 18-80

    • OSA diagnosis

    • CPAP therapy indication

    Exclusion Criteria:
    • Previous CPAP therapy

    • Severe COPD

    • Respiratory insufficiency

    • Obesity-hypoventilation syndrome

    • Cardiac failure

    • Recent cerebrovascular disease

    • Central apnea, Cheyne Stokes or similar

    • Important nasal insufficiency or malformation

    • Previous pharyngeal surgery

    • Shift work

    • Psychosocial disability

    • Refusal to participate

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hospital Universitario Araba Vitoria-Gasteiz Alava Spain 01004

    Sponsors and Collaborators

    • Basque Health Service

    Investigators

    • Principal Investigator: Mikel Azpiazu, MD, Basque Health Service

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Mikel Azpiazu, Principal Investigator, Basque Health Service
    ClinicalTrials.gov Identifier:
    NCT03734341
    Other Study ID Numbers:
    • 2017-37
    First Posted:
    Nov 7, 2018
    Last Update Posted:
    Jan 9, 2019
    Last Verified:
    Jan 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Mikel Azpiazu, Principal Investigator, Basque Health Service
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 9, 2019